PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials

JCM, Free Full-Text

Frontiers Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Myopathy with statin–fibrate combination therapy: clinical considerations

Coenzyme Q10 and Statin Myalgia: What is the Evidence?

Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology

The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update - Canadian Journal of Cardiology

The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations: Molecular Therapy

Full article: Statin-induced myopathy: a review and update

Cholesterol Lowering Drugs - Endotext - NCBI Bookshelf

Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle‐related side‐effects - Sivashanmugarajah - 2019 - Internal Medicine Journal - Wiley Online Library

Mechanisms of Statin-Induced Myopathy Arteriosclerosis, Thrombosis, and Vascular Biology